AS2521780

®

MedChemExpress

Cat. No.: CAS No.: Molecular Formula: Molecular Weight: Target: Pathway: Storage:	HY-12663 1214726-89-2 C ₃₀ H ₄₁ N ₇ OS 547.76 PKC Epigenetics; TGF-beta/Smad Please store the product under the recommended conditions in the Certificate of Analysis.	
---	--	--

BIOLOGICAL ACTIVITY					
BIOEOGICAL ACTIVITY					
Description	AS2521780 is a novel PKC θ selective inhibitor with an IC ₅₀ of 0.48 nM.				
IC₅₀ & Target	РКСӨ 0.48 nM (IC ₅₀)	ΡΚCε 18 nM (IC ₅₀)	ΡΚCα 160 nM (IC ₅₀)	ΡΚCδ 160 nM (IC ₅₀)	
In Vitro	AS2521780 exerts potent inhibition of recombinant human PKCθ enzyme activity (IC ₅₀ =0.48 nM), which is more than 30-fold higher than that of other PKC isoforms. Further, AS2521780 exerts little or no inhibition on other protein kinases. AS2521780 suppresses CD3/CD28-induced Interleukin-2 (IL-2) gene transcription in Jurkat T cells and proliferation of human primary T cells. AS2521780 also suppresses concanavalin A-induced cytokine production by rat splenocytes and monkey peripheral blood mononuclear cells with similar potency ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.				
In Vivo	AS2521780 significantly reduces paw swelling in a dose-dependent manner in a rat model of adjuvant-induced arthritis ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.				

PROTOCOL)
Cell Assay ^[1]	Human peripheral T cells are incubated with AS2521780 and anti-human CD28 (0.5 μg/mL). After 48 h incubation, cell proliferation is detected using a CellTiter-Glo Luminescent Cell Viability Assay ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[1]	AS2521780 or vehicle is orally administered twice daily from Day 1 to 24. On Day 25, the left hind paw of each rat is dissected above the ankle joint and fixed in 10% neutral buffered formalin. After decalcification, the paws are embedded in paraffin, sectioned longitudinally and stained with hematoxylin and eosin ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

• Cell Cycle. 2021 Feb 22;1-11.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Fukahori H, et al. Effect of AS2521780, a novel PKC0 selective inhibitor, on T cell-mediated immunity. Eur J Pharmacol. 2014 Dec 15;745:217-22.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA